Tardive Dyskinesia Clinical Trial
Official title:
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 31, 2024 |
Est. primary completion date | November 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: For the non-TD group: 1. Prescribed and taking an antipsychotic medication for 90-days or longer. 2. Tardive Dyskinesia symptoms if present are not from Parkinsons, Tourette's syndrome, Huntington disease. 3. Signed an informed consent. 4. Speaks English fluently. Exclusion Criteria: 1. Suffered a moderate or severe head injury in the last year; 2. History of a learning disorder or developmental disability that would inhibit a patient from completing the TD protocol. 3. Severe visual impairment that is cannot be corrected by glasses or contacts. |
Country | Name | City | State |
---|---|---|---|
United States | Fermata Helath | Brooklyn | New York |
United States | Charak Research Center | Garfield Heights | Ohio |
Lead Sponsor | Collaborator |
---|---|
iRxReminder | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AIMS Score | Abnormal Involuntary Scale Score | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02840760 -
Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
|
N/A | |
Completed |
NCT01688037 -
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
|
Phase 2 | |
Completed |
NCT01391390 -
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
|
N/A | |
Withdrawn |
NCT03254186 -
Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Completed |
NCT02291861 -
Addressing Involuntary Movements in Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT02274558 -
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT02198794 -
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT01467089 -
The Assessment of Movement Disorders Utilizing Live Two-Way Video
|
N/A | |
Completed |
NCT04794413 -
Pimavanserin Treatment in TS
|
Early Phase 1 | |
Recruiting |
NCT05859698 -
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
|
Phase 4 | |
Active, not recruiting |
NCT02252380 -
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
|
N/A | |
Terminated |
NCT00917293 -
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
|
Phase 2 | |
Completed |
NCT01543321 -
Xenazine in Late Dyskinetic Syndrome With Neuroleptics
|
Phase 3 | |
Completed |
NCT02405091 -
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT03176771 -
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Terminated |
NCT02524886 -
Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
|
N/A | |
Completed |
NCT02195700 -
Aim to Reduce Movements in Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Completed |
NCT02736955 -
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT03497013 -
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
|
N/A | |
Withdrawn |
NCT01908452 -
Pyridoxal Kinase Activity in Tardive Dyskinesia
|
Phase 3 |